Spinal cord injury (SCI) often leads to persistent motor deficits, spasticity, and neuropathic pain, with limited treatment options that rarely fully reverse functional loss. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulation technique that delivers pulsed magnetic fields to target brain regions, has emerged as a promising approach to promote functional recovery by harnessing the brain’s inherent neuroplasticity. This blog synthesizes key findings from three pivotal studies, highlighting rTMS’s underlying molecular mechanisms, clinical efficacy in real-world settings, and data-driven optimization strategies for advancing SCI rehabilitation.

How rTMS Drives Repair: Molecular Pathways Uncovered

A preclinical study on SCI mice (Zhang et al., 2024) revealed that high-frequency rTMS enhances recovery by precisely targeting the Cx43-autophagy-mTOR axis—a critical regulatory network disrupted in the aftermath of spinal cord damage. Specifically, after SCI, astrocytes (a type of glial cell essential for spinal cord homeostasis) overexpress connexin 43 (Cx43), a protein that forms gap junctions. This overexpression not only impairs autophagic flux (the process by which cells clear damaged components) but also exacerbates neuroinflammation and tissue scarring, two major barriers to recovery. High-frequency rTMS was shown to suppress Cx43 expression in astrocytes, which in turn restored normal autophagic function (evidenced by increased LC3II levels and reduced p62 accumulation) and activated the mTOR pathway—an upstream regulator of cell growth and repair that elevates levels of key molecules like mTOR, phosphorylated mTOR (p-mTOR), and phosphorylated 4EBP1 (p-4EBP1). Behaviorally, rTMS-treated mice exhibited significantly higher Basso Mouse Scale (BMS) scores (a gold standard for assessing hindlimb motor function in SCI models) over a 28-day observation period, alongside improved motor-evoked potentials (MEP) that indicated enhanced communication between the brain and spinal cord. This study is particularly impactful as it links rTMS to specific, druggable molecular targets, laying a critical foundation for translating preclinical findings to human trials.

Clinical Insights: rTMS in SCI Rehabilitation

A comprehensive review (Fan et al., 2025) synthesizes decades of clinical research to outline rTMS’s role in SCI rehabilitation and identify avenues for improvement. Its therapeutic benefits stem from three interconnected mechanisms: neural circuit reorganization (promoting cortical plasticity and reconfiguring damaged spinal networks), restoration of excitatory-inhibitory balance (reducing abnormal hyperactivity of motor neurons that causes spasticity), and microenvironmental improvement (dampening neuroinflammation and enhancing the survival of regenerating neurons). Clinical data from small to medium-sized trials consistently show that rTMS improves key functional outcomes—for example, patients with chronic SCI reported increased walking speed, improved grip strength, and reduced reliance on assistive devices—while also alleviating spasticity (a common complication that limits mobility) and neuropathic pain (which affects up to 80% of SCI patients and is often refractory to conventional painkillers). However, the review notes that variability in stimulation protocols (e.g., frequency, intensity, target region) and patient populations (e.g., acute vs. chronic SCI, level of injury) contributes to inconsistent results across studies. To address this, novel stimulation paradigms like intermittent theta-burst stimulation (iTBS) (which delivers shorter, more intense pulses) and paired associative stimulation (PAS) (combining rTMS with peripheral nerve stimulation) have been developed, offering shorter treatment durations (as little as 5 minutes per session vs. 30 minutes for traditional rTMS) and superior efficacy in preliminary trials. The authors also emphasize that combining rTMS with regenerative therapies (e.g., neural precursor cell transplantation) or assistive technologies (e.g., exoskeletons) may yield synergistic effects, though standardized protocols and large-scale randomized controlled trials (RCTs) are needed to validate these approaches and establish rTMS as a mainstream therapy.

Optimizing rTMS: Insights from Computational Modeling

A landmark simulation study (Bey et al., 2012) addressed a longstanding gap in rTMS research: how key stimulation parameters (intensity vs. frequency) shape neural responses in the brain. Using a biologically realistic neuronal network model, the researchers simulated rTMS’s effects on local field potentials (LFPs)—electrical signals that reflect the collective activity of neural populations—and analyzed changes in power across major brain wave frequencies (delta, theta, alpha, beta, gamma). Their key finding was that stimulation intensity—not frequency—primarily dictates rTMS’s effects on brain oscillations: gamma band power (linked to cognitive and motor processing) increased linearly with intensity, while alpha and beta band power (associated with rest and motor inhibition) decreased in a dose-dependent manner. Delta and theta bands, which play roles in memory and recovery, showed more nuanced, intensity-specific changes. This model is invaluable for explaining conflicting results in clinical studies—for example, why two trials using the same frequency but different intensities might report divergent outcomes—and provides a data-driven framework for personalizing rTMS dosing. By using this model to tailor intensity to individual patients (based on factors like brain anatomy and injury severity), clinicians can maximize therapeutic efficacy while minimizing side effects (e.g., mild headaches, transient dizziness), which are rare but more common at higher intensities.

Key Takeaways for Clinicians & Patients

1. Mechanistic Targets: rTMS modulates the Cx43-autophagy-mTOR axis to reduce scarring, restore cellular homeostasis, and promote repair after SCI (Zhang et al., 2024).
2. Functional Benefits: Beyond motor recovery, rTMS alleviates spasticity and neuropathic pain—two debilitating SCI complications—and novel protocols like iTBS make treatment more accessible (Fan et al., 2025).
3. Parameter Optimization: Intensity should be prioritized over frequency when designing rTMS protocols; computational models can guide personalized dosing (Bey et al., 2012).
4. Future Directions: Combining rTMS with regenerative therapies or assistive technologies holds great promise, but large-scale RCTs are needed to standardize protocols.

Conclusion

rTMS represents a paradigm shift in SCI care, bridging preclinical insights into molecular repair, real-world clinical benefits, and computational optimization to deliver a non-invasive, low-risk therapy. For patients with SCI—who often face limited options for functional improvement—rTMS offers not just physical benefits but also a renewed sense of hope. While challenges remain, including protocol standardization and validating long-term efficacy, the cumulative evidence from molecular, clinical, and modeling studies underscores its potential as a cornerstone of modern neurorehabilitation. As research continues to refine stimulation paradigms and expand our understanding of its mechanisms, rTMS may soon transition from a promising experimental therapy to a first-line treatment for SCI, transforming the lives of millions worldwide.

References

1. Bey, A., Leue, S., & Wienbruch, C. (2012). A neuronal network model for simulating the effects of repetitive transcranial magnetic stimulation on local field potential power spectra. PLoS ONE, 7(11), e49097. https://doi.org/10.1371/journal.pone.0049097
2. Fan, S., Wang, W., & Zheng, X. (2025). Repetitive transcranial magnetic stimulation for the treatment of spinal cord injury: Current status and perspective. International Journal of Molecular Sciences, 26(2), 825. https://doi.org/10.3390/ijms26020825
3. Zhang, L., Xiao, Z., Su, Z., et al. (2024). Repetitive transcranial magnetic stimulation promotes motor function recovery in mice after spinal cord injury via regulation of the Cx43-autophagy loop. Journal of Orthopaedic Surgery and Research, 19(1), 387. https://doi.org/10.1186/s13018-024-04879-6